IASO207 injection for relapsed or resistant B-cell lymphoma
Part of Cancer clinical trials.
This early-stage trial tests IASO207, a new injection designed to treat B-cell lymphomas (blood cancers) that have come back or stopped responding to standard treatments. The drug targets a protein called CD19 found on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old
- Diagnosed with specific types of B-cell lymphoma (such as DLBCL, follicular lymphoma, or Richter transformation) that returned or didn't respond to prior standard chemotherapy and antibody therapy
- Cancer cells test positive for CD19 protein
- At least one measurable tumor lesion visible on imaging
- Adequate organ function (heart, lungs, liver, kidneys, blood counts) confirmed by recent lab tests
- No prior CD19-targeted treatments or certain other recent cancer therapies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new combination treatment for a type of lymphoma (B-cell non-Hodgkin's lymphoma) that has a protein called CD20 on its cells. It may be an option if you have not received certain previous therapies and your lymphoma is measurable, to see if the combination can help control the disease.
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
This trial tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if IASO206 can help control the cancer.
This trial tests a new type of cell therapy (IASO206) for patients whose autoimmune hemolytic anemia (a condition where the body attacks its own red blood cells) has not responded to standard treatments. The therapy is designed to target and control the immune cells causing the problem.
Hear when a new Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.